DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for AL amyloidosis — screening already-approved drugs against its 39-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAL amyloidosis maps to a 39-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for al amyloidosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysozyme (LYZ) — LYZ is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet tvgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5LSH · 1.061 Å · ligand propyl beta-D-galactofuranoside (TVG). Experimental structure, not a prediction.
What the evidence adds up to
In 2009 the disease was described as a progressive condition caused by monoclonal light chains whose specific mutations make them misfold into partially stable intermediates that self-aggregate into oligomers and then into cross β-sheet amyloid fibrils. At least eleven other proteins from different organs can produce systemic amyloidoses that are clinically hard to distinguish from AL amyloidosis. All these deposits share Congo red staining with green birefringence under polarised light and rigid non-branching fibrils 7.5 to 10 nm in diameter. The abstract stated that unequivocal identification of the fibril-forming protein is essential for choosing treatment, but it did not report any survival data, response rates, or sample sizes.
A 2017 case report described a patient whose extensive skin thickening and hardening led to repeated diagnoses of scleroderma, but treatment for that condition was not effective. After serum and urine protein electrophoresis and bone marrow flow cytometry, a diagnosis of primary AL amyloidosis was established. This single case adds no quantitative evidence on treatment outcomes.
A 2020 bioinformatics study analysed the gene expression profile GSE73040, which contained specimens from 9 AL amyloidosis patients and 5 normal controls. It identified 1464 differentially expressed genes (727 up-regulated, 737 down-regulated) linked to ribosome biogenesis and immune response. Protein–protein interaction network analysis highlighted ITGAM, ITGB2, ITGAX, IMP3 and FBL as candidate genes. Using connectivity map data, the authors proposed AT-9283, Ritonavir and a PKC beta-inhibitor as potential drugs. The study did not test any of these agents in patients or animal models, and the sample size of 9 patients is very small for a disease with heterogeneous organ involvement.
What is still missing: prospective trials that test the proposed small molecules in patients with confirmed AL amyloidosis, a reliable method to stratify patients by the specific misfolding-prone light chain mutation, and funding to move from bioinformatic predictions to clinical testing. The 2009 review noted that distinguishing AL from other amyloidoses requires definitive protein identification, yet the 2020 study did not address how its candidate genes or drugs would be validated against that diagnostic requirement.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Haematologica · 2009 · 67 citations · open access
Current treatment of AL amyloidosis
AbstractImmunoglobulin light chain systemic amyloidosis(AL) is a progressive disease caused by monoclonallight chains with specific mutations that confer a unique propensity to misfold from their native structure to less stable, partially folded intermediates that self-aggregate into oligomers and then into the highly-ordered cross β-sheet structure which defines amyloid fibrils.1 At least 11 additional proteins, synthesized by different organs (liver, intestine, etc) can cause systemic amyloidoses which can be difficult to distinguish from AL amyloidosis on a clinical basis. These proteins form amyloid deposits that share the common tinctorial, green birefringence under polarized light after staining with Congo red, and ultrastructural features, rigid, non-branching fibril with a distinct diameter of 7.5 to 10 nm (Figure 1). The unequivocal identification of the protein forming the amyloid fibril is essential for the choice of
AbstractINTRODUCTION: Amyloid light chain (AL) results from the deposition of immunoglobulin light chain fragments, and can affect multiple organs/systems. Our patient was diagnosed as scleroderma repeatedly because of extensive skin thickening and hardening, but the treatment was not effective. We did extensive laboratory examinations including serum/urine protein electrophoresis and flow cytometry assay of bone marrow aspiration. CONCLUSION: A diagnosis of primary AL amyloidosis was established.
Pharmacogenomics and Personalized Medicine · 2020 · 5 citations · open access
<p>Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach</p>
AbstractObjective: Systemic amyloid light chain (AL) amyloidosis is a rare plasma cell disease. However, the regulatory mechanisms of AL amyloidosis have not been thoroughly uncovered, identification of candidate genes and therapeutic agents for this disease is crucial to provide novel insights into exploring the regulatory mechanisms underlying AL amyloidosis. Methods: The gene expression profile of GSE73040, including 9 specimens from AL amyloidosis patients and 5 specimens from normal control, was downloaded from GEO datasets. Differentially expressed genes (DEGs) were sorted with regard to AL amyloidosis versus normal control group using Limma package. The gene enrichment analyses including GO and KEGG pathway were performed using DAVID website subsequently. Furthermore, the protein–protein interaction (PPI) network for DEGs was constructed by Cytoscape software and STRING database. DEGs were mapped to the connectivity map datasets to identify potential molecular agents of AL amyloidosis. Results: A total of 1464 DEGs (727 up-regulated, 737 down-regulated) were identified in AL amyloidosis samples versus control samples, these dysregulated genes were associated with the dysfunction of ribosome biogenesis and immune response. PPI network and module analysis uncovered that several crucial genes were defined as candidate genes, including ITGAM, ITGB2, ITGAX, IMP3 and FBL . More importantly, we identified the small molecular agents (AT-9283, Ritonavir and PKC beta-inhibitor) as the potential drugs for AL amyloidosis. Conclusion: Using bioinformatics approach, we have identified candidate genes and pathways in AL amyloidosis, which can extend our understanding of the cause and molecular mechanisms, and these crucial genes and pathways could act as biomarkers and therapeutic targets for AL amyloidosis. Keywords: light chain amyloidosis, bioinformatics approach, differentially expressed genes, candidate genes, therapeutic agent
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
